Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Al Blunt"'
Publikováno v:
Journal of Clinical Oncology. 38:e15622-e15622
e15622 Background: Historically, oncology drug development can take years to accomplish the goal of bringing new agents to patients. Scientific knowledge is evolving rapidly, transforming our understanding of the diseases at a rapid pace. This necess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0daf3090c08696d9af0a8130c2e053dd
https://doi.org/10.1200/jco.2020.38.15_suppl.e15622
https://doi.org/10.1200/jco.2020.38.15_suppl.e15622
Publikováno v:
Journal of Clinical Oncology. 38:e15632-e15632
e15632 Background: STING activating cyclic-di-nucleotides result in the production of interferons, activating immune cells. We show that “Precision Medicine Knowledge Frames” (PMKF) are analyses inherently involving 2 processes: Frame 1 – Bench
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4297fe05ab199c1f9d572a8739619f86
https://doi.org/10.1200/jco.2020.38.15_suppl.e15632
https://doi.org/10.1200/jco.2020.38.15_suppl.e15632
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ann Cleverly, Karim A. Benhadji, M. Fuchs, Teresa Macarulla, Denis Pezet, Joerg Trojan, Mark Kozloff, Michael Lahn, Davide Melisi, Al Blunt, Gael Deplanque, Helmut Oettle, Ivelina Gueorguieva, Durisala Desaiah, Josep Tabernero, Rocio Garcia-Carbonero
Publikováno v:
Cancer Research. 76:CT068-CT068
Background: Transforming growth factor-beta (TGFβ) signaling pathway is active in PC. In preclinical in vivo models, TGFβ inhibitors enhanced activity of gemcitabine. In this study, patients with Stage II to IV unresectable PC were treated with GG
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4f7730134dcab20d90a77260d79e42e
https://doi.org/10.1158/1538-7445.am2016-ct068
https://doi.org/10.1158/1538-7445.am2016-ct068
Autor:
Rocio Garcia-Carbonero, Gael Deplanque, Denis Pezet, Al Blunt, Ann Cleverly, Teresa Macarulla, Karim A. Benhadji, Mark Kozloff, Jörg Trojan, Josep Tabernero, Martin Fuchs, Ivelina Gueorguieva, Michael Lahn, Durisala Desaiah, Davide Melisi, Helmut Oettle
Publikováno v:
Journal of Clinical Oncology. 34:4019-4019
4019Background: In vivo preclinical models, transforming growth factor-beta (TGFβ) inhibitors enhanced gemcitabine activity. In this study, patients (pts) with Stage II to IV unresectable PC were treated with GG or GP to evaluate their efficacy and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5fe517d5b02c601a2d32323f6ca2388a
https://doi.org/10.1200/jco.2016.34.15_suppl.4019
https://doi.org/10.1200/jco.2016.34.15_suppl.4019
Autor:
Ivelina Gueorguieva, Durisala Desaiah, Tamara Nadal, Mark Kozloff, Rocio Garcia Carbonero, Al Blunt, Ann Cleverly, Michael Lahn, Teresa Macarulla, Sada Pillay, Josep Tabernero
Publikováno v:
Journal of Clinical Oncology. 31:2563-2563
2563 Background: Based on animal studies, the combination of a TGF-β inhibitor and gemcitabine is expected to enhance antitumor activity of gemcitabine. Hence, we started a combination study of LY with gemcitabine to assess the safety of this combin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60091d3d10b709ca9e397a5088c6f348
https://doi.org/10.1200/jco.2013.31.15_suppl.2563
https://doi.org/10.1200/jco.2013.31.15_suppl.2563
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.